Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 2, 2014, Pages 175-185

  Cobo Ibáñez, Tatiana ^a   Loza Santamaría, Estíbaliz ^b   Pego Reigosa, José María ^c   Marqués, Alejandro Olivé ^d   Rúa Figueroa, Íñigo ^e   Fernández Nebro, Antonio ^f   Cáliz, Rafael Cáliz ^g   López Longo, Francisco Javier ^h   Muñoz Fernández, Santiago ^a  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b Institute for Health   (Spain)

^c Hospital Meixoeiro Edificio Anexo   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Rituximab; Systematic review; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ANEMIA; ARTHRITIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOCOMPLEMENTEMIA; IMMUNOSUPPRESSIVE TREATMENT; MENTAL DISEASE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SKIN MANIFESTATION; STEROID THERAPY; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 84927511205     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.04.002     Document Type: Review

References (35)

1. Sousa E., Isenberg D. Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. Best Pract Res Clin Rheumatol 2009, 23:563-574.
2. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513.
3. Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., Portales-Pérez D., Baranda L., Abud-Mendoza C., et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006, 8:R83.
4. Gunnarsson I., Sundelin B., Jonsdottir T., Jacobson S.H., Henriksson E.W., van Vollenhoven R.F. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007, 56:1263-1272.
5. Murray E., Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010, 29:707-716.
6. Lan L., Han F., Chen J.H. Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. J Zhejiang Univ Sci B 2012, 13:731-744.
7. Pego-Reigosa J.M., Cobo-Ibáñez T., Calvo-Alén J., Loza-Santamaría E., Rahman A., Muñoz-Fernández S., et al. Efficacy and safety of non-biologic immunosuppressants in the treatment of non-renal systemic lupus erythematosus: a systematic review. Arthritis Care Res 2013, 65:1775-1785.
8. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, et al. Oxford Centre for evidence-based medicine levels of evidence. 〈〉; 2011 [accessed 15.01.14]. http://www.cebm.net/index.aspx?o=1025.
9. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
10. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
11. Merrill J., Buyon J., Furie R., Latinis K., Gordon C., Hsieh H.J., et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011, 20:709-716.
12. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580-2589.
13. Tanaka Y., Yamamoto K., Takeuchi T., Nishimoto N., Miyasaka N., Sumida T., et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007, 17:191-197.
14. Gottenberg J.E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005, 64:913-920.
15. Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006, 54:2970-2982.
16. Catapano F., Chaudhry A.N., Jones R.B., Smith K.G., Jayne D.W. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 2010, 25:3586-3592.
17. Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007, 66:470-475.
18. Jonsdottir T., Gunnarsson I., Risselada A., Henriksson E.W., Klareskog L., van Vollenhoven R.F. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008, 67:330-334.
19. Lindholm C., Borjesson-Asp K., Zendjanchi K., Sundqvist A.C., Tarkowski A., Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008, 35:826-833.
20. Galarza C., Valencia D., Tobon G.J., Zurita L., Mantilla R.D., Pineda-Tamayo R., et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?. Clin Rev Allergy Immunol 2008, 34:124-128.
21. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005, 44:1542-1545.
22. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007, 66:1259-1262.
23. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61:482-487.
24. Turner-Stokes T., Lu T.Y., Ehrenstein M.R., Giles I., Rahman A., Isenberg D.A. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 2011, 50:1401-1408.
25. Albert D., Dunham J., Khan S., Stansberry J., Kolasinski S., Tsai D., et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008, 67:1724-1731.
26. Reynolds J.A., Toescu V., Yee C.S., Prabu A., Situnayake D., Gordon C. Effects of rituximab on resistant SLE disease including lung involvement. Lupus 2009, 18:67-73.
27. Karpouzas G.A., Gogia M., Moran R., Cooray D.V. Rituximab therapy induces durable remissions in patients with refractory systemic lupus erythematosus. Ann Rheum Dis 2009, 68:248. [Abstract].
28. Terrier B., Amoura Z., Ravaud P., Hachulla E., Jouenne R., Combe B., et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010, 62:2458-2466.
29. Garcia-Carrasco M., Mendoza-Pinto C., Sandoval-Cruz M., Soto-Vega E., Beltran-Castillo A., Jimenez-Hernandez M., et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 2010, 19:213-219.
30. Ramos-Casals M., Garcia-Hernandez F.J., de Ramon E., Callejas J.L., Martinez-Berriotxoa A., Pallares L., et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010, 28:468-476.
31. Chen H., Zheng W., Su J., Xu D., Wang Q., Leng X., et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus a prospective pilot study. Rheumatology (Oxford) 2011, 50:1640-1644.
32. Pinto L.F., Velasquez C.J., Prieto C., Mestra L., Forero E., Marquez J.D. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus 2011, 20:1219-1226.
33. Diaz-Lagares C., Perez-Alvarez R., Garcia-Hernandez F.J., Ayala-Gutierrez M.M., Callejas J.L., Martinez-Berriotxoa A., et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 2011, 13:13.
34. Vital E.M., Dass S., Buch M.H., Henshaw K., Pease C.T., Martin M.F., et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011, 63:3038-3047.
35. Fernandez-Nebro A., de la Fuente J.L., Carreno L., Izquierdo M.G., Tomero E., Rua-Figueroa I., et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus 2012, 21:1063-1076.